X

NYSE:ARA Investor Alert: Deadline in Lawsuit against American Renal Associates Holdings Inc on October 31, 2016

The Shareholders Foundation announced that a deadline is coming up on October 31, 2016 in the lawsuit filed for certain investors in NYSE:ARA shares over alleged securities laws violations by American Renal Associates Holdings.

Investors who purchased shares of American Renal Associates Holdings Inc (NYSE:ARA) have certain options and there are strict and short deadlines running. Deadline: October 31, 2016. NYSE:ARA stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

The plaintiff alleges on behalf of all persons or entities who purchased or otherwise acquired American Renal securities pursuant and/or traceable to American Renal’s false and misleading Registration Statement and Prospectus issued in connection with the Company’s initial public offering on or about April 21, 2016 (the “IPO” or the “Offering”) and/or on the open market between April 21, 2016 and August 18, 2016, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between Defendants made false and/or misleading statements and/or failed to disclose that American Renal Associates Holdings Inc was engaged in a fraudulent scheme to steer patients away from qualified-for Medicare and Medicaid plans into more expensive Affordable Care Act (“ACA”) plans to obtain greater reimbursement for the Company’s dialysis services, that the foregoing scheme was in violation of federal and state laws, and that as a result of the foregoing, American Renal Associates Holdings’ public statements were materially false and misleading at all relevant times.

Those who purchased NYSE:ARA shares have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

John:
Related Post